Picture loading failed.

Pre-Made Racotumomab biosimilar, Whole Mab: Anti-Idiotope of Anti-NeuGc-ganliosides therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Racotumomab (trade name Vaxira) is a therapeutic cancer vaccine for the treatment of solid tumors that is currently under clinical development by Recombio, an international public-private consortium with the participation of the Center of Molecular Immunology at Havana, Cuba (CIM) and researchers from Buenos Aires University and National University of Quilmes in Argentina. It induces the patient's immune system to generate a response against a cancer-specific molecular target with the purpose of blocking tumor growth, slowing disease progression and ultimately increasing patient survival.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-463-1mg 1mg 3090
GMP-Bios-ab-463-10mg 10mg Inquiry
GMP-Bios-ab-463-100mg 100mg Inquiry
GMP-Bios-ab-463-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Racotumomab biosimilar, Whole Mab: Anti-Idiotope of Anti-NeuGc-ganliosides therapeutic antibody
INN Name Racotumomab
TargetIdiotope of anti-NeuGc-ganliosides
FormatWhole mAb
DerivationMouse
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2008
Year Recommended2009
CompaniesCenter of Molecular Immunology;Elea;Innogene Kalbiotech;Recombio
Conditions ApprovedNon-small cell lung cancer
Conditions ActiveNeuroblastoma
Conditions DiscontinuedBreast cancer;Colorectal cancer;Malignant melanoma;Small cell lung cancer;Solid tumours
Development Techna